Georgantas Robert William III 4
4 · BIODESIX INC · Filed Mar 18, 2022
Insider Transaction Report
Form 4
BIODESIX INCBDSX
Georgantas Robert William III
DirectorSVP, Rsrch & Trans'l Science
Transactions
- Award
Stock Options (Right to buy)
2022-03-10+2,842→ 5,685 totalExercise: $0.77Exp: 2030-04-14→ Common Stock (2,842 underlying) - Award
Stock Options (Right to buy)
2021-02-23+2,843→ 2,843 totalExercise: $0.77Exp: 2030-04-14→ Common Stock (2,843 underlying)
Footnotes (3)
- [F1]On April 15, 2020, the Reporting Person was granted an option to purchase 5,685 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.
- [F2]On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 2,843 shares underlying the option.
- [F3]On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 2,842 shares underlying the option.